FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,077 letters match. Newest first.

  1. Everything Sprouts, LLC

    FDA warns Everything Sprouts of insanitary conditions at its Minneapolis sprout operation, including roof leaks and condensate dripping onto exposed sprouts.

    High risk
  2. Yiling Pharmaceutical Ltd.

    FDA warns Yiling Pharmaceutical over manufacturing violations causing cross-contamination risks in finished drugs from shared equipment.

    High risk
  3. Huangshi Hygienic Material Medicine Co., Ltd.

    Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.

    High risk
  4. Kingdom Creamery of Vermont LLC

    FDA found Listeria monocytogenes in Kingdom Creamery's ready-to-eat dairy plant and cited sanitation and CGMP failures.

    High risk
  5. AACE Pharmaceuticals, Inc.

    AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.

    High risk
  6. Wailea Agricultural Group, Inc.

    Wailea Agricultural Group's hearts of palm were adulterated after FDA found E. coli in water used for handwashing and cleaning.

    High risk
  7. Sedecal S.A.

    Sedecal S.A. warned for quality-system and reporting failures on mobile x-ray systems.

    High risk
  8. Reunipeche SAS

    Reunipeche SAS's seafood safety plan (HACCP) for whole fresh fish lacks adequate hazard controls and monitoring, FDA says.

    High risk
  9. Rey de los Camarones S. A.

    FDA warns Rey de los Camarones over sea cucumber food safety plan (HACCP) violations.

    High risk
  10. Golden Grains Bakery

    FDA warns Golden Grains Bakery over repeated preventive-control failures for RTE Blender Bombs, including metal detection and Listeria risks.

    High risk
  11. Kabe Labortechnik GmbH

    Kabe Labortechnik lacked validated processes and design controls for SAFE-T-FILL blood collection tubes, FDA found.

    High risk
  12. NeuroSync, Inc.

    FDA warned NeuroSync, Inc. that its EYE-SYNC eye-assessment device was adulterated by design control, CAPA, supplier and acceptance failures, plus unreported correction and missing UDI.

    High risk
  13. Product Society LLC

    FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.

    High risk
  14. Microspecialties, LLC

    FDA warned Microspecialties, a Connecticut contract device maker, after it shipped unsterilized eye-surgery injection kits labeled sterile.

    High risk
  15. Wuxi Medical Instrument Factory Co., Ltd.

    FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.

    High risk
  16. NWL Netherlands Services B.V.

    FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.

    High risk
  17. Skye Biologics Holdings LLC

    FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.

    High risk
  18. Breadbox Co.

    Breadbox Co. made ready-to-eat bakery products under insanitary conditions without a required food safety plan, FDA says.

    High risk
  19. Eden F&C Co., Ltd

    FDA warns Eden F&C over seafood HACCP failures for ready-to-eat fish sausage corn dogs.

    High risk
  20. Yeshua Bendito, C.A.

    FDA says Yeshua Bendito's Venezuelan RTE crab meat in reduced oxygen packaging is adulterated due to serious seafood HACCP violations.

    High risk
  21. Excelvision Fareva

    Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.

    High risk
  22. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk
  23. OSRX, Inc.

    OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.

    High risk
  24. Mentha & Allied Products Private Ltd.

    FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.

    High risk
  25. Shantou S.E.Z. Baojie Industry Co., Ltd.

    FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.

    High risk
  26. Tailstorm Health Inc. dba Medivant Health

    Tailstorm Health (Medivant Health) sterile compounded drugs had insanitary conditions and current good manufacturing practice failures, prompting a bevacizumab recall.

    High risk
  27. Taizhou Jingshang Cosmetics Technology Co., Ltd.

    FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

    High risk
  28. BioAsia Worldwide Sdn Bhd

    FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.

    High risk
  29. Cosco International, Inc.

    FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.

    High risk
  30. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  31. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  32. Livestock Nutrition Center

    Livestock Nutrition Center made non-medicated animal feed contaminated with monensin, killing animals; FDA found preventive control failures.

    High risk
  33. Noah Medical Corporation

    FDA warns Noah Medical of San Jose, CA over quality system failures and missed injury reports for its Galaxy bronchoscopes.

    High risk
  34. ICU Medical

    ICU Medical warned for changed Medfusion 4000 and CADD Solis infusion pumps sold without required FDA clearances.

    High risk
  35. Empower Clinic Services, LLC dba Empower Pharma

    FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.

    High risk
  36. PMS4PMS, LLC

    FDA warns PMS4PMS of Clarence, NY, over CGMP failures and an unapproved menstrual cramp relief cream.

    High risk
  37. Nubratori, Inc. dba Nubratori Rx

    FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.

    High risk
  38. EpiCare Acquisitions, LLC

    FDA warns EpiCare Acquisitions over unvalidated EpiCare-Zenith lasers and flawed complaint, corrective-action, record, training, and reporting procedures.

    High risk
  39. Yangzhou Sion Commodity Co., Ltd.

    FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.

    High risk
  40. Annovex Pharma, Inc.

    FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.

    High risk
  41. Aspen Biopharma Labs Private Limited

    FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.

    High risk
  42. Dexcom, Inc.

    FDA warned Dexcom over quality-system and design-control failures for G6 and G7 glucose monitors, including an unapproved sensor component change.

    High risk
  43. Hangzhou Glamcos Biotech Co., Ltd.

    Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.

    High risk
  44. Advanced Pharmaceutical Technology

    FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.

    High risk
  45. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk
  46. MG Infusions

    FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.

    High risk
  47. International Laboratories Corp

    FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.

    High risk
  48. Aspen Pharmacare Holdings Limited

    FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.

    High risk
  49. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  50. Vegewax Candleworx Ltd.

    FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.

    High risk